Shares of Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company.
A number of research analysts recently commented on the stock. Wall Street Zen upgraded shares of Stevanato Group from a “hold” rating to a “buy” rating in a research note on Friday. Morgan Stanley initiated coverage on Stevanato Group in a research report on Monday, December 1st. They issued an “equal weight” rating and a $24.00 target price on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Stevanato Group in a research note on Monday, December 29th.
Get Our Latest Stock Analysis on STVN
Hedge Funds Weigh In On Stevanato Group
Stevanato Group Price Performance
Stevanato Group stock opened at €17.22 on Friday. The business’s 50-day simple moving average is €21.14 and its 200 day simple moving average is €23.49. The company has a quick ratio of 1.30, a current ratio of 1.89 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 1.58 and a beta of 0.58. Stevanato Group has a 12-month low of €16.30 and a 12-month high of €28.00.
Stevanato Group Company Profile
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
See Also
- Five stocks we like better than Stevanato Group
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buy This Stock at 9:30 AM on MONDAY!
- A U.S. “birthright” claim worth trillions – activated quietly
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
